Literature DB >> 24849899

Preliminary production of 211At at the Texas A&M University Cyclotron Institute.

Thomas Michael Martin1, Vihar Bhakta, Abeer Al-Harbi, Michael Hackemack, Gabriel Tabacaru, Robert Tribble, Sriram Shankar, Gamal Akabani.   

Abstract

A feasibility study for the production of the alpha particle-emitting radionuclide At was performed at the Texas A&M University Cyclotron Institute as part of the Interdisciplinary Radioisotope Production and Radiochemistry Program. The mission of this program centers upon the production of radionuclides for use in diagnostic and therapeutic nuclear medicine with the primary focus on development of novel therapeutic strategies. As a first step in establishing this program, two goals were outlined: (i) verify production of At and compare results to published data, and (ii) evaluate shielding and radiological safety issues for large-scale implementation using an external target. The radionuclide At was produced via the Bi (α, 2n) At reaction using the K500 cyclotron. Two experiments were conducted, using beam energies of 27.8 MeV and 25.3 MeV, respectively. The resulting yields for At were found to be 36.0 MBq μA h and 12.4 MBq μA h, respectively, which fall within the range of published yield data. Strategies for increasing absolute yield and production efficiency were also evaluated, which focused chiefly on using a new target designed for use with the K150 cyclotron, which will enable the use of a higher beam current. Finally, neutron and gamma dose rates during production were evaluated by using the Monte Carlo code MCNPX. It was determined that a simple structure consisting of 4-in thick borated polyethylene will reduce the neutron dose rate within the cyclotron production vault by approximately a factor of 2, thereby decreasing activation of equipment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24849899     DOI: 10.1097/HP.0000000000000042

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  2 in total

Review 1.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Authors:  Mehran Makvandi; Edouard Dupis; Jonathan W Engle; F Meiring Nortier; Michael E Fassbender; Sam Simon; Eva R Birnbaum; Robert W Atcher; Kevin D John; Olivier Rixe; Jeffrey P Norenberg
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

2.  Simulation of the distribution of astatine-211 solution dispersion in a lab room.

Authors:  Hitoshi Kubo; Kazuhiro Takahashi; Saki Shimoyama; Songji Zhao; Naoyuki Ukon; Hiroshi Ito
Journal:  Nucl Med Commun       Date:  2021-09-01       Impact factor: 1.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.